中剂量地舒单抗治疗纤维性结构不良的安全性与疗效:一项2期临床试验的观察性结果
本项2期试验的观察性结果显示,6例重启中剂量地舒单抗(120 mg/3个月)的成人纤维性结构不良患者,其血清骨转换标志物变化与高剂量方案相当,18F-NaF PET/CT病灶活性及高摄取病灶体积绝对变化无差异;但2例重症患者出现剂量间反跳,1例复发高钙血症。
要点
- 中剂量地舒单抗(120 mg/3个月)在成人纤维性结构不良中可能提供与高剂量方案相当的临床获益。
- 6例重启中剂量治疗者中,2例重症患者出现剂量间反跳,1例复发高钙血症。
- 疗效持续时间差异是重要的潜在安全性担忧。
核心结论
- 中剂量地舒单抗可能为成人纤维性结构不良提供与高剂量方案相当的临床获益,同时可能降低相关风险,但疗效持续时间差异是重要的潜在安全性担忧。
研究设计与样本
- 2期临床试验(NCT03571191)的观察性结果,纳入成人纤维性结构不良患者,8例接受高剂量地舒单抗治疗6个月后观察8个月,方案修订后6例在临床需要时重启中剂量地舒单抗(120 mg/3个月)。
主要发现
- 6例重启中剂量治疗者中,初始与最终剂量时血清标志物变化相当:I型前胶原氨基端前肽中剂量组-82% vs 高剂量组-91%,C端肽中剂量组-86% vs 高剂量组-86%。
- 中剂量与高剂量方案之间,18F-NaF PET/CT病灶活性或高摄取病灶体积绝对变化无差异。
- 1例连续组织学分析显示中剂量治疗下病灶矿化进行性增加、细胞密度降低。
- 中剂量治疗下4例骨转换标志物持续下降,但2例重症患者在剂量间出现反跳,其中1例复发高钙血症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Fibrous dysplasia (FD) is a rare skeletal mosaic disease associated with fractures and disability. A phase 2 trial of the RANKL inhibitor denosumab (NCT03571191) reported profound reductions in lesion activity and increased lesional mineralization after 6 months of high-dose treatment. Denosumab was well tolerated; however, discontinuation was associated with severe hypercalcemia. OBJECTIVE: Investigate the safety and efficacy of moderate-dose denosumab (120 mg/3 months) compared to the standard high-dose regimen. SETTING: Clinical research center. PATIENTS: Adults with FD. INTERVENTIONS: Eight adults received high-dose denosumab for 6 months (120 mg/month with loading doses on weeks 2 and 3) followed by an 8-month posttreatment observation. The protocol was amended to restart moderate-dose denosumab (120 mg/3 months) if clinically indicated. MAIN OUTCOME MEASURES: Bone turnover markers, 18F-sodium fluoride positron emission tomography/computed tomography (18F-NaF PET/CT), lesion biopsies. RESULTS: In 6 subjects who restarted moderate-dose treatment, changes in serum markers at the initial and final dose were comparable (procollagen type 1 N-terminal propeptide -82% and -91%, C-terminal telopeptide -86% and -86% for moderate- and high-dose, respectively). There was no difference in 18F-NaF PET/CT lesional activity or absolute change in avid lesion volume between moderate- and high-dose regimens. Sequential tissue histological analyses in 1 subject demonstrated progressive lesional mineralization and reduced cellularity with moderate-dose treatment. Bone turnover markers on moderate-dose treatment showed a sustained decline in 4 subjects; however, 2 severely affected subjects developed rebound between doses, with recurrent hypercalcemia in 1 subject. CONCLUSION: Moderate-dose denosumab may provide clinical benefits comparable to the high-dose regimen in adults with FD while potentially lowering associated risks. However, discrepancies in the duration of efficacy are an important potential safety concern.
引用
- Szymczuk V, Elbashir II, Ahmed R, et al. Safety and Efficacy of Moderate-dose Denosumab in Fibrous Dysplasia: Observational Results From a Phase 2 Clinical Trial. J Clin Endocrinol Metab. 2025. PMID: 39673171. doi:10.1210/clinem/dgae867
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。